Adult, but no pediatric, anaphylaxis-related deaths in the Finnish population from 2014 to 2023 Authors: Jaakob Semken, Sauli Palmu, Jennifer L.P. Protudjer, Jussi Karjalainen, Heini Huhtala, Sandra Ekström, Inger Kull, Juho E. Kivistö Published: 2026 To the Editor: Severe anaphylaxis affects up to 2% of individuals during their lifetime, with mortality estimated at 0.5 to 1 deaths per million person-years worldwide1 We previously reported a low incidence of anaphylaxis deaths among adults, and no deaths in children.2 During the past decade, however, the incidence of allergic reactions leading to hospitalization has been increasing in Finland among both adults and children.3,4 Similar trends of increasing incidence of anaphylaxis have been reported in multiple countries.1 The number of anaphylaxis-related deaths from 2014 onward remains unknown. To this end, we have now aimed to investigate the epidemiology of anaphylaxis-related deaths in the Finnish population between 2014 and 2023 and identify the primary eliciting agents and causes of fatal anaphylaxis. This study was based on death certificates from the Finnish Official Cause-of-Death Database, which is considered virtually complete thanks to cross-checking with the national population register. Causes of death in Finland are determined from medical or forensic evidence, and accuracy is enhanced by autopsies, which are performed in 87.2% of accidental deaths. We included cases classified under International Disease Classification, 10th Revision, codes T78.0 to T78.4, T63, T88.6, and T88.7 between 2014 and 2023. Copies of the original death certificates were obtained from Statistics Finland and retrospectively reviewed to confirm whether the anaphylaxis criteria defined by Sampson et al5 were met. Annual age-specific population data were obtained from the Official Statistics of Finland. Incidence rates of anaphylaxis-related deaths (per 1,000,000 person years) with 95% CIs were calculated by using the entire Finnish population, with individuals younger than 18 years classified as children. Poisson regression was applied to assess differences in incidence, and sex-based comparisons were performed using the Fisher exact test (2 sided). P values less than .05 were considered statistically significant. Analyses were conducted with Stata 19.5 software (StataCorp LLC, College Station, Tex). During the 10-year study period (2014-2023), 43 Finnish adults and no children died from anaphylaxis. The number of deaths ranged from 0 to 8 annually, corresponding to incidences of 0.09 to 1.27 per million person years (Fig 1). When the data were analyzed in 2-year intervals and compared with our earlier results from 1996 to 2013, the previously substantiated trend of an increasing incidence of anaphylaxis-related deaths2 continued during the earlier part of the current study period (2014-2019) (incidence rate ratio = 1.89; P = .003; 95% CI = 1.25-2.87). However, this upward trend was followed by a marked decline in mortality during the latter half of the study (2020-2023) (incidence rate ratio = 0.24; P = .001; 95% CI = 0.10-0.57). The cumulative incidence of anaphylaxis deaths was 0.78 per million person years.Fig 1Annual number and incidence (per 1,000,000 person-years) with 95% CI of anaphylaxis-related deaths in the Finnish population between 2014-2023 in 2-year periods. Annual number and incidence (per 1,000,000 person-years) with 95% CI of anaphylaxis-related deaths in the Finnish population between 2014-2023 in 2-year periods. Overall, 53.5% of anaphylaxis-related deaths occurred in males and 46.5% occurred in females, although this difference was not statistically significant (P = .76). Most deaths occurred in health care units (44%), at home (21%), or outdoors (12%). The mean age at death was 65.2 years (range 23-90 years). The leading cause was insect stings (28%), followed by food (19%) and antibiotics (16%) (Table I). Causal foods included peanut, honey, buckwheat, strawberry, fish, banana, and 1 unspecified food. Deaths due to insect stings accounted for 8 of the 23 cases involving male patients (35%) and 4 of the 20 cases involving female patients (20%), although this difference was not statistically significant (P = .33). Of the 43 patients experiencing anaphylaxis-related deaths, 14 had received adrenaline after exposure.Table ICauses of anaphylaxis-related deaths and distribution by age in the Finnish population from 2014 to 2023.AgentAge group (y)<18 (n = 0)18-64 (n = 26)≥65 (n = 17)All (N = 43)No.%No.%No.%No.%Pharmaceutical001038.5952.91944.2 Analgesic——13.8——12.3 Anesthetic——13.8——12.3 Antibiotic——311.5423.5716.3 Antineoplastic and immunomodulating agents——27.7211.849.3 Cardiovascular system———————— Contrast agent————15.912.3 Blood and blood-forming organs————15.912.3 Local anesthetic————15.912.3 Other pharmaceutical——311.5——37Nonpharmaceutical001453.8635.32046.5 Insect sting——934.6317.61227.9 Food——519.2317.6818.6 Snake bite———————— Plant————————Unknown0027.7211.749.3Pharmaceutical agents were classified according to the Anatomical Therapeutic Chemical Classification System. Table ICauses of anaphylaxis-related deaths and distribution by age in the Finnish population from 2014 to 2023.AgentAge group (y)<18 (n = 0)18-64 (n = 26)≥65 (n = 17)All (N = 43)No.%No.%No.%No.%Pharmaceutical001038.5952.91944.2 Analgesic——13.8——12.3 Anesthetic——13.8——12.3 Antibiotic——311.5423.5716.3 Antineoplastic and immunomodulating agents——27.7211.849.3 Cardiovascular system———————— Contrast agent————15.912.3 Blood and blood-forming organs————15.912.3 Local anesthetic————15.912.3 Other pharmaceutical——311.5——37Nonpharmaceutical001453.8635.32046.5 Insect sting——934.6317.61227.9 Food——519.2317.6818.6 Snake bite———————— Plant————————Unknown0027.7211.749.3Pharmaceutical agents were classified according to the Anatomical Therapeutic Chemical Classification System. Causes of anaphylaxis-related deaths and distribution by age in the Finnish population from 2014 to 2023. Pharmaceutical agents were classified according to the Anatomical Therapeutic Chemical Classification System. Most patients experienced loss of consciousness (88%) after allergen exposure, and 49% of patients experienced respiratory compromise following allergen exposure. In total, 91% of the patients fulfilled the anaphylaxis criteria created by Sampson et al.5 We previously reported a low but increasing incidence of anaphylaxis in Finland between 1996 and 2013, with no pediatric deaths during that period (in that analysis, individuals younger than 16 years were considered children).2 The present study extends these findings, demonstrating an internationally low, but continued, increase in anaphylaxis incidence and a persistent absence of anaphylaxis-related deaths among children in Finland from 2014 to 2023. It can therefore be stated that no anaphylaxis-related pediatric deaths have occurred over a 28-year period (1996-2023). The reason for the absence of pediatric deaths in Finland remains unclear, but it may be partly attributable to good asthma care among the pediatric population, which is demonstrated by a very low incidence of death due to asthma among Finnish children.6 Moreover, children are much more likely to survive the hypotension and vascular spasm associated with anaphylaxis. The evidence-informed allergy and asthma care in children may partly be due to the Finnish Allergy Programme, which was instituted in 2008 with the aim of increasing immunologic tolerance and education regarding allergies. For comparison, 8 fatal instances of anaphylaxis were reported in children in Germany between 2009 and 2020, and national mortality analyses in the United States reported 84 anaphylaxis-related deaths among children aged 0 to 17 years during an observation period from 1999 to 2009.7,8 We have previously reported that the incidence of anaphylaxis in Finland increased between 1999 and 2020.3 Considering this increasing incidence, a corresponding increase in anaphylaxis-related mortality might have been anticipated and was in fact observed in the earlier part of the study period. The findings demonstrated in this study seem to follow global trends, as several studies report rising rates of anaphylaxis and anaphylaxis-related mortality in many countries.1 This study showed a lower incidence of anaphylaxis-related deaths from 2020 to 2023, which may correlate with the coronavirus disease 2019 (COVID-19) pandemic. Social measures such as lockdowns, which altered viral circulation and population exposure patterns, as well as vaccination campaigns and changes in health care utilization, could potentially explain this trend. A recent study from a pediatric emergency department in Montréal, Canada, reported a decline in the frequency of anaphylaxis early during the COVID-19 pandemic.9 However, data on Finnish adults from 2020 showed no significant drop in severe allergic reactions, with hospitalizations continuing to rise and emergency room visits decreasing slightly.3 In a multinational analysis of data from the European Anaphylaxis Registry and national health statistics, males were more frequently (accounting for 66% of cases) affected in fatal anaphylactic reactions.7 During an observation period between 1999 and 2020, Finnish females accounted for 59% of patients hospitalized because of allergic reactions.10 The increased male mortality and higher female hospitalization rates could in part be the result of men potentially having a higher threshold for seeking treatment. No statistical difference between males and females in our data could be determined. This study provides valuable data on temporal trends in anaphylaxis-related mortality in a well-defined national population. Comparable studies from other countries examining secular trends in anaphylaxis-related deaths remain scarce. A key strength of our study is that 91% of the patients fulfilled the anaphylaxis criteria established by Sampson et al.5 In addition, the internationally recognized Anatomical Therapeutic Chemical Classification System was used to classify pharmaceutical agents. Importantly, the analysis was based on comprehensive nationwide data, as all anaphylaxis-related deaths were identified through the Finnish Cause-of-Death Registry, which has virtually complete coverage of mortality in the country. The present study also has some limitations. Anaphylaxis can be difficult to identify, and International Disease Classification, 10th Revision, coding may not capture all cases. Even the criteria proposed by Sampson et al may miss certain presentations.5 It is possible that some cases may have been missed owing to difficulty of diagnostics. Moreover, some severe anaphylaxis events may go unwitnessed, or the causative substance may not be identified. Some deaths due to anaphylaxis may have been misdiagnosed as coronary events. Reliance on death certificates means that the available information on the circumstances surrounding each fatal event was somewhat limited. In conclusion, a total of 43 anaphylaxis-related deaths among Finnish adults were recorded between 2014 and 2023, with no fatalities reported in children. The overall incidence was 0.78 per million person years. An initial upward trend in mortality was observed, followed by a marked decline during the latter part of the study period (2020-2023). Slightly more deaths occurred in males than in females. Pharmaceuticals and insect stings accounted for 72% of the fatal cases. Most deaths occurred either at home or within health care settings. Disclosure statement Supported by the Tampere Tuberculosis Foundation, Foundation of the Finnish Anti-Tuberculosis Association, Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital, Väinö and Laina Kivi Foundation, Allergiatutkimussäätiö, and Research Foundation of the Pulmonary Diseases. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.